Home

Gynecologic Pathology

Other Sub-Specialists

Christina Isacson, M.D.

Primary Contact

Gynecologic Pathology Practice Leader - Ellen S. Pizer, M.D., Ph.D.

Ellen S. Pizer, M.D., Ph.D.

After graduating magna cum laude in Biology from Harvard University, Dr. Pizer obtained her Medical Degree from the University of Texas Southwestern Medical Center in Dallas. She went on to earn her Graduate Ph.D. by completing the Medical Scientist Training program at the same institute. Dr. Pizer then began her tenure at the Johns Hopkins institutions completing her internship, residency, and a two-year fellowship in Gynecological Pathology and Molecular Pathology. Dr.

Full Bio

Why CellNetix?

  • Two board certified pathologists with fellowship training in Gynecologic Pathology
  • 94% of our biopsy results are returned within 48 hours
  • Automatic correlation of biopsy results with previous Pap test
  • 97% of Pap tests reported within 72 hours (including pathologist review)
  • 24/7 priority access to your local pathologists
  • Customized monthly data summaries to assist physicians’ staff with scheduling follow up visits and managing patient care

 

  • Reports convey information clearly, concisely and correctly
  • Intra-operative consultations with patients’ primary physician, oncologist, surgeon and radiologist ensure multidisciplinary care for cancer patients
  • State-of-the-art Information Technology systems with EMR interface capabilities
  • Full service billing department for direct billing of patient insurance, as well as payment plans for cash-paying patients
  • Customizable test requisitions

Our two fellowship trained sub-specialists in Gynecologic Pathology provide a broad range of services to physicians and their patients, including diagnosis and staging for patients undergoing surgical treatment of gynecologic cancers, diagnosis of cervical biopsies and correlation with previous pathology and Pap tests, HPV DNA testing, pathologic diagnosis for patients with benign diseases of the genital tract, and pathologic examination of placentas. Our Gynecologic Pathology sub-specialty is led by Dr. Ellen Pizer, and Dr. Christina Isacson.

Our Strengths

CellNetix coordinates and leads the gynecologic tumor boards at its various institutions, and supports high risk/hereditary cancer services. CellNetix’ quality program mandates that all new cancers are reviewed by a second pathologist for quality assurance. Our state-of-the-art bar-coding system has been shown to reduce common histologic slide identification errors by 95% and overall case identification errors by 62%.

  • Two board certified pathologists with fellowship training in Gynecologic Pathology
  • 94% of our biopsy results are returned within 48 hours
  • Automatic correlation of biopsy results with previous Pap test
  • 97% of Pap tests reported within 72 hours (including pathologist review)
  • 24/7 priority access to your local pathologists
  • Reports convey information clearly, concisely and correctly
  • Intra-operative consultations with patients’ primary physician, oncologist, surgeon and radiologist ensure multidisciplinary care for cancer patients
  • State-of-the-art Information Technology systems with EMR interface capabilities
  • Full service billing department for direct billing of patient insurance, as well as payment plans for cash-paying patients
  • Customizable test requisitions
  • Customized monthly data summaries to assist physicians’ staff with scheduling follow up visits and managing patient care

Our Gynecologic Pathologists are available to provide their expertise for questions, evaluations and second opinions on all cases pertaining to their specialty.

Types of Testing We Do

Pathologic diagnosis of biopsies and surgical resections of the female genital tract.

  • HPV DNA testing
  • Testing for Gonorrhea, Chlamydia and HPV from liquid Pap vial
  • Pap test interpretation from SurePath® and ThinPrep® liquid vials as well as conventional smears
Types of Conditions and Diseases We Test for:
  • Endometrial cancer
  • Cervical cancer
  • Ovarian cancer
  • Fallopian tube cancer
  • Endometriosis
  • Uterine leiomyomas (fibroids)

Links

References

  • The 2006 Consensus Guidelines for the Management of Women with Abnormal Cervical Cancer Screening Tests:  American Journal of Obstetrics and Gynecology (2007;197(4); 346-355).
  • Statement on HPV DNA test utilization.  Solomon D, Papillo JL, Davey DD; Cytopathology Education and Technology Consortium.  Acta Cytol. 2009 May-Jun;53(3):247-8; discussion 249-52. PMID: 19534262   
  • Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Pecorelli S. Int J Gynaecol Obstet. 2009 May;105(2):103-4. PMID: 19367689   
  • Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS, Muto MG.J Clin Oncol. 2007. 25(25):3985-90. PMID: 17761984   
  • Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. Semmel DR, Folkins AK, Hirsch MS, Nucci MR, Crum CP. Mod Pathol. 2009. PMID: 19407856